MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562878 | Name: Nebivolol HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nebivolol HCl is a selective beta1-receptor antagonist.

Chemical Structure

Nebivolol HCl
Nebivolol HCl
CAS#152520-56-4

Theoretical Analysis

MedKoo Cat#: 562878

Name: Nebivolol HCl

CAS#: 152520-56-4

Chemical Formula: C22H26ClF2NO4

Exact Mass:

Molecular Weight: 441.90

Elemental Analysis: C, 59.80; H, 5.93; Cl, 8.02; F, 8.60; N, 3.17; O, 14.48

Price and Availability

Size Price Availability Quantity
10mg USD 240.00
50mg USD 550.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Nebivolol HCl; Nebivolol Hydrochloride; Silostar; Bystolic, R-67145; R 67145; R67145;
IUPAC/Chemical Name
(R)-1-((R)-6-fluorochroman-2-yl)-2-(((S)-2-((S)-6-fluorochroman-2-yl)-2-hydroxyethyl)amino)ethan-1-ol hydrochloride
InChi Key
JWEXHQAEWHKGCW-FNLXBVDKSA-N
InChi Code
InChI=1S/C22H25F2NO4.ClH/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22;/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2;1H/t17-,18+,21-,22+;
SMILES Code
O[C@@H]([C@H]1CCC2=C(O1)C=CC(F)=C2)CNC[C@H](O)[C@@H]3CCC4=C(O3)C=CC(F)=C4.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker.
In vitro activity:
After 24 h of AA exposure, significantly reduced cell viability and intracellular ROS overproduction were observed in EAhy926 cells; both effects were counteracted by NEB (nebivolol) pretreatment. After 48 h of exposure to AA, the most prominent metabolite changes were significant decreases in arginine, glutamate, glutamine and glutathione levels, along with a significant increase in the aspartate, glycerophosphocholine and UDP-N-acetylglucosamine contents. NEB pretreatment slightly inhibited the changes in glutathione and glycerophosphocholine. Reference: Toxins (Basel). 2022 Feb 10;14(2):132. https://pubmed.ncbi.nlm.nih.gov/35202159/
In vivo activity:
Treatment with nebivolol (10 mg/kg/day; p.o. gavage) prevented the increase of both superoxide (O2•-) and thiobarbituric acid reactive substances (TBARS) in the left ventricle of rats chronically treated with ethanol. Nebivolol prevented ethanol-induced increase of Nox2 expression in the left ventricle. Reference: Cardiovasc Toxicol. 2021 Mar;21(3):224-235. https://pubmed.ncbi.nlm.nih.gov/33067693/
Solvent mg/mL mM comments
Solubility
DMF 20.0 45.26
DMSO 65.6 148.33
Ethanol 2.5 5.57
Water 1.8 4.05
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 441.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Antoine MH, Husson C, Yankep T, Mahria S, Tagliatti V, Colet JM, Nortier J. Protective Effect of Nebivolol against Oxidative Stress Induced by Aristolochic Acids in Endothelial Cells. Toxins (Basel). 2022 Feb 10;14(2):132. doi: 10.3390/toxins14020132. PMID: 35202159; PMCID: PMC8876861. 2. Chen Q, Jiang H, Wang Z, Cai LY, Jiang YC, Xie L, Zhou Y, Zeng X, Ji N, Shen YQ, Chen QM. Adrenergic Blockade by Nebivolol to Suppress Oral Squamous Cell Carcinoma Growth via Endoplasmic Reticulum Stress and Mitochondria Dysfunction. Front Pharmacol. 2021 Aug 12;12:691998. doi: 10.3389/fphar.2021.691998. PMID: 34456721; PMCID: PMC8387679. 3. do Vale GT, da Silva CBP, Sousa AH, Gonzaga NA, Parente JM, Araújo KM, Castro MM, Tirapelli CR. Nebivolol Prevents Up-Regulation of Nox2/NADPH Oxidase and Lipoperoxidation in the Early Stages of Ethanol-Induced Cardiac Toxicity. Cardiovasc Toxicol. 2021 Mar;21(3):224-235. doi: 10.1007/s12012-020-09614-1. Epub 2020 Oct 16. PMID: 33067693. 4. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, Schulz E, Mollnau H, von Sandersleben A, Kleschyov AL, Mülsch A, Li H, Förstermann U, Münzel T. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006 Oct;48(4):677-84. doi: 10.1161/01.HYP.0000239207.82326.29. Epub 2006 Aug 28. PMID: 16940222.
In vitro protocol:
1. Antoine MH, Husson C, Yankep T, Mahria S, Tagliatti V, Colet JM, Nortier J. Protective Effect of Nebivolol against Oxidative Stress Induced by Aristolochic Acids in Endothelial Cells. Toxins (Basel). 2022 Feb 10;14(2):132. doi: 10.3390/toxins14020132. PMID: 35202159; PMCID: PMC8876861. 2. Chen Q, Jiang H, Wang Z, Cai LY, Jiang YC, Xie L, Zhou Y, Zeng X, Ji N, Shen YQ, Chen QM. Adrenergic Blockade by Nebivolol to Suppress Oral Squamous Cell Carcinoma Growth via Endoplasmic Reticulum Stress and Mitochondria Dysfunction. Front Pharmacol. 2021 Aug 12;12:691998. doi: 10.3389/fphar.2021.691998. PMID: 34456721; PMCID: PMC8387679.
In vivo protocol:
1. do Vale GT, da Silva CBP, Sousa AH, Gonzaga NA, Parente JM, Araújo KM, Castro MM, Tirapelli CR. Nebivolol Prevents Up-Regulation of Nox2/NADPH Oxidase and Lipoperoxidation in the Early Stages of Ethanol-Induced Cardiac Toxicity. Cardiovasc Toxicol. 2021 Mar;21(3):224-235. doi: 10.1007/s12012-020-09614-1. Epub 2020 Oct 16. PMID: 33067693. 2. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, Schulz E, Mollnau H, von Sandersleben A, Kleschyov AL, Mülsch A, Li H, Förstermann U, Münzel T. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006 Oct;48(4):677-84. doi: 10.1161/01.HYP.0000239207.82326.29. Epub 2006 Aug 28. PMID: 16940222.
1: Abdel-Fattah L, Abdel-Aziz L, El-Kosasy A, Gaied M. Quantification of nebivolol hydrochloride in human plasma by liquid chromatography using fluorescence detection: Use in pharmacokinetic study. Drug Discov Ther. 2010 Dec;4(6):418-22. PubMed PMID: 22491307. 2: Hussar DA. New drugs 09, part 1. Plast Surg Nurs. 2009 Oct-Dec;29(4):228-36; quiz 237-8. doi: 10.1097/PSN.0b013e3181d0512c. Review. PubMed PMID: 20029303. 3: Bundkirchen A, Brixius K, Bölck B, Nguyen Q, Schwinger RH. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. Eur J Pharmacol. 2003 Jan 26;460(1):19-26. PubMed PMID: 12535855.

View History

SU-200

SU-200